EU Marketing Approval Gap Between Lilly’s Donamemab and Eisai’s Leqembi Could Narrow

 
• By Francesca Bruce
  
Lilly's Alzheimer's drug donamemab is up for discussion at this month's CHMP meeting
(Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Product Reviews